<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-id journal-id-type="hwp">spcep</journal-id>
<journal-title>Cephalalgia</journal-title>
<issn pub-type="ppub">0333-1024</issn>
<issn pub-type="epub">1468-2982</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0333102412447537</article-id>
<article-id pub-id-type="publisher-id">10.1177_0333102412447537</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Correspondence</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Nummular headache with and without exacerbations: Comparative characteristics in a series of 72 patients*</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Guerrero</surname><given-names>Ángel L</given-names></name>
<xref ref-type="corresp" rid="corresp1-0333102412447537"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Cortijo</surname><given-names>Elisa</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Herrero-Velázquez</surname><given-names>Sonia</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Mulero</surname><given-names>Patricia</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Miranda</surname><given-names>Sara</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Peñas</surname><given-names>María Luz</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Pedraza</surname><given-names>María Isabel</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Fernández</surname><given-names>Rosa</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0333102412447537">Neurology Department, Hospital Clínico Universitario, Valladolid, Spain</aff>
<author-notes>
<corresp id="corresp1-0333102412447537">Ángel L Guerrero, Neurology Department, Hospital Clínico Universitario, Avda Ramón y Cajal 3, 47005 Valladolid, Spain Email: <email>gueneurol@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>8</issue>
<fpage>649</fpage>
<lpage>653</lpage>
<history>
<date date-type="received"><day>21</day><month>10</month><year>2011</year></date>
<date date-type="rev-recd"><day>19</day><month>12</month><year>2011</year></date>
<date date-type="rev-recd"><day>3</day><month>2</month><year>2012</year></date>
<date date-type="rev-recd"><day>26</day><month>3</month><year>2012</year></date>
<date date-type="accepted"><day>7</day><month>4</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© International Headache Society 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">International Headache Society</copyright-holder>
</permissions>
<abstract>
<p><italic>Objectives</italic>: Apart from the characteristic chronic head pain in a coin-shaped circumscribed area, superimposed exacerbations have been described from early reports of nummular headache (NH). In a prospective series, we aim to compare the demographic and clinical characteristics between cases of exacerbations (ENH) and non-exacerbations (NENH) in NH.</p>
<p><italic>Methods and results:</italic> Seventy-two NH patients (44 female, 28 male) attending a headache outpatient office. As eight patients presented with bifocal NH we analysed 80 painful areas; 47 (58.8%) presented <italic>in situ</italic> exacerbations. Mean intensity of exacerbations was 7.5 ± 1.6 and they lasted 5.7 ± 11.6 minutes. Exacerbation quality was mostly stabbing. We found no differences between ENH and NEHN groups in age at onset, baseline pain intensity, size of painful area, allodynia or other sensory symptoms, or baseline pain quality. There were no differences between populations with respect to relief with symptomatic therapy, requirement of preventative therapy and its response to preventatives.</p>
<p><italic>Conclusion: In situ</italic> exacerbations superimposed on baseline pain are frequent in NH and might be included in diagnostic criteria. No statistically significant differences were found between ENH and NENH cases in demographic and nosological characteristics, or needing or response to therapy, but these sample sizes are small.</p>
</abstract>
<kwd-group>
<kwd>Epicrania</kwd>
<kwd>exacerbations</kwd>
<kwd>nummular headache</kwd>
<kwd>preventative therapy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0333102412447537"><title>Objectives</title>
<p>Nummular headache (NH) (from the Latin ‘nummus’ meaning ‘coin’) was described in 2002 by Pareja et al. (<xref ref-type="bibr" rid="bibr1-0333102412447537">1</xref>) in a series of 13 cases with focal pain, felt in a circumscribed rounded or elliptical area of head surface, typically 1–6 cm in diameter. Two years later NH was included in the research diagnostic criteria of the International Classification of Headache Disorders, 2nd edition (ICHD-II) (<xref ref-type="bibr" rid="bibr2-0333102412447537">2</xref>) (<xref ref-type="table" rid="table1-0333102412447537">Table 1</xref>).
<table-wrap id="table1-0333102412447537" position="float"><label>Table 1.</label><caption><p>Proposed diagnostic criteria for nummular headache (ICDH-II, International Classification of Headache Disorders, 2nd edition).</p></caption>
<graphic alternate-form-of="table1-0333102412447537" xlink:href="10.1177_0333102412447537-table1.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td>A</td>
<td align="left">Mild to moderate head pain, fulfilling criteria B and C</td></tr>
<tr>
<td>B</td>
<td align="left">Pain is felt exclusively in a round or elliptical area, typically 2–6 cm in diameter</td></tr>
<tr>
<td>C</td>
<td align="left">Pain is chronic and either continuous or interrupted by spontaneous remissions lasting weeks to months</td></tr>
<tr>
<td>D</td>
<td align="left">Not attributed to another disorder</td></tr>
</tbody>
</table>
</table-wrap></p>
<p>Apart from the mild-to-moderate intensity baseline pain, many patients usually experience superimposed exacerbations, lasting from several seconds to hours. Although exacerbations are mentioned in diagnostic criteria and some series of patients, we hereby firstly analyse comparative characteristics between exacerbations (ENH) and non-exacerbations (NENH) nummular headache cases.</p>
</sec>
<sec id="sec2-0333102412447537" sec-type="methods"><title>Methods</title>
<p>We prospectively evaluated consecutive new patients with NH diagnosed accordingly to ICHD-II research criteria, attending a headache outpatient office located in a tertiary hospital from January 2008 to October 2011. Seventy-two patients (44 female, 28 male) out of 1560 (4.6%) attending were diagnosed with NH. As eight patients presented with bifocal NH we analysed the clinical characteristics of 80 painful areas.</p>
<p>We obtained a complete history for each patient, including precipitant events or coexistence of other types of headache. We considered age at onset and sex, and evaluated characteristics of baseline pain (quality, intensity, temporal pattern, location, size, shape) and exacerbations (quality, intensity and duration). Regarding temporal pattern, we considered chronic NH when there were no significant remission periods, episodic NH when remission periods longer than 3 months were noticed, and recent when time from onset was less than 12 months. The presence of triggers of exacerbations was also considered. Subsequently, we performed a complete physical and neurological examination including inspection, palpation and sensory examination of the painful area. We considered in each patient relief provided with symptomatic treatment and requirement and efficacy of preventative therapies. Neuroimaging study (magnetic resonance or computerized tomography of the head when first was not possible) and routine blood work-up, always including erythrocyte sedimentation rate and antinuclear antibodies, were carried out, with no abnormalities in all cases.</p>
<p>We finally compared demographic, clinical and therapeutic characteristics between ENH and NENH groups using conveniently unpaired <italic>t</italic>-test and chi-square test. Statistical analysis was performed with SPSS 15.0 software. Significance level was established at 0.05 (two-tailed).</p>
<p>Our first 30 NH cases (<xref ref-type="bibr" rid="bibr3-0333102412447537">3</xref>), including four bifocal (<xref ref-type="bibr" rid="bibr4-0333102412447537">4</xref>), have already been published.</p>
</sec>
<sec id="sec3-0333102412447537" sec-type="results"><title>Results</title>
<p>Mean age at onset of NH in 72 patients was 47.3 ± 18.5 years (range 12–82). As eight patients presented with bifocal NH we analysed 80 painful areas. Temporal pattern was chronic in 30 areas (37.6%), episodic in 31 (38.7%) and recent in 19 (23.7%). Forty-two (52.5%) were right-sided, 32 (40%) left-sided, and six (7.5%) sagittal. Most frequent locations were occipital (26.3%), parietal (23.8%) and frontal (18.8%). The shape of the painful area was mainly rounded (80%). Qualities of baseline pain were mostly pressing (33.8%), stabbing (31.3%) or burning (23.8%). Intensity (0–10 on a visual analogical scale (VAS)) was 5.7 ± 2.6 (range 1–9). In 35 areas (43.8%) numbness was spontaneously disclosed by the patients, associating paraesthesia in 16 (20%). Tenderness to palpation was found in 29 areas (36.3%).</p>
<p>There were <italic>in situ</italic> exacerbations in 47 areas (58.8%). Intensity of exacerbations was 7.5 ± 1.6 (range 4–10) and they lasted 5.7 ± 11.6 minutes. Exacerbation quality was mostly stabbing (59.6%). In three patients in our series, exacerbations were triggered by head movements and in one of them also by coughing or sneezing.</p>
<p>Among the 72 patients, 20 (27.7%) did not respond to analgesics (defined as less than 50% pain relief), and in 42 (58.3%) a preventative was required, achieving at least 50% pain relief in 34 (80.9%) patients. The most widely used drug was gabapentin (37 patients, 51.4%) titrated between 800 and 1800 mg/day. In six patients gabapentin was not helpful and lamotrigine dosed between 100 and 200 mg/day was used instead.</p>
<p>We found no statistically significance differences between ENH and NENH groups in demographic variables (age at onset, female/male ratio) and baseline pain characteristics (intensity, quality, size of painful area, allodynia or other sensory symptoms). There was no difference between populations with regard to relief with symptomatic therapy, requirement of preventative therapy and its response to preventatives. Although differences between groups were large in some variables, statistical significance was not attained, probably due to the small sample size. A comparison of the characteristics of both groups and results of the statistical testing are summarized in <xref ref-type="table" rid="table2-0333102412447537">Table 2</xref>.
<table-wrap id="table2-0333102412447537" position="float"><label>Table 2.</label><caption><p>Main features of exacerbation and non-exacerbation groups.</p></caption>
<graphic alternate-form-of="table2-0333102412447537" xlink:href="10.1177_0333102412447537-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="2">Variables</th>
<th>ENH (<italic>n</italic> = 47)</th>
<th>NENH (<italic>n</italic> = 33)</th>
<th><italic>p</italic></th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="2">Demographic<sup><xref ref-type="table-fn" rid="table-fn2-0333102412447537">a</xref></sup></td>
<td align="left">Age at onset (mean ± SD)</td>
<td align="left">48.3 ± 17.3</td>
<td align="left">53.1 ± 20.0</td>
<td align="left">0.27<sup><xref ref-type="table-fn" rid="table-fn4-0333102412447537">1</xref></sup></td></tr>
<tr>
<td align="left">Sex (F/M)</td>
<td align="left">27/16</td>
<td align="left">17/12</td>
<td align="left">0.70<sup>2</sup></td></tr>
<tr>
<td align="left">Temporal pattern</td>
<td align="left">Ch/Epis/Rec</td>
<td align="left">16/16/15</td>
<td align="left">14/15/4</td>
<td align="left">0.11<sup>2</sup></td></tr>
<tr>
<td rowspan="6">Baseline pain</td>
<td align="left">Intensity VAS (mean ± SD)</td>
<td align="left">5.9 ± 3.0</td>
<td align="left">5.4 ± 1.9</td>
<td align="left">0.39<sup><xref ref-type="table-fn" rid="table-fn4-0333102412447537">1</xref></sup></td></tr>
<tr>
<td align="left">Character (% Pressing/Stabbing)</td>
<td align="left">38.3/25.5</td>
<td align="left">27.3/39.4</td>
<td align="left">0.48<sup>2</sup></td></tr>
<tr>
<td align="left">Location (% Occ/Par/Fr)</td>
<td align="left">29.8/23.4/23.4</td>
<td align="left">21.2/24.2/12.1</td>
<td align="left">0.54<sup>2</sup></td></tr>
<tr>
<td align="left">Size (cm)</td>
<td align="left">4.6 ± 1.5</td>
<td align="left">4.4 ± 1.1</td>
<td align="left">0.47<sup><xref ref-type="table-fn" rid="table-fn4-0333102412447537">1</xref></sup></td></tr>
<tr>
<td align="left">Shape (R/E)</td>
<td align="left">36/11</td>
<td align="left">28/5</td>
<td align="left">0.36<sup>2</sup></td></tr>
<tr>
<td align="left">Sensory symptoms or signs</td>
<td align="left">36.2%</td>
<td align="left">54.5%</td>
<td align="left">0.15<sup>2</sup></td></tr>
<tr>
<td rowspan="3">Therapy<sup><xref ref-type="table-fn" rid="table-fn2-0333102412447537">a</xref></sup></td>
<td align="left">Relief with analgesics</td>
<td align="left">64.3%</td>
<td align="left">79.3%</td>
<td align="left">0.28<sup>2</sup></td></tr>
<tr>
<td align="left">Preventative requirement</td>
<td align="left">60.5%</td>
<td align="left">55.1%</td>
<td align="left">0.65<sup>2</sup></td></tr>
<tr>
<td align="left">Response to preventatives<sup><xref ref-type="table-fn" rid="table-fn3-0333102412447537">b</xref></sup></td>
<td align="left">80.8%</td>
<td align="left">81.2%</td>
<td align="left">0.96<sup>2</sup></td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0333102412447537"><p>ENH: exacerbations nummular headache; NENH: non-exacerbations nummular headache; SD: standard deviation; F/M: female/male; Ch/Epis/Rec: chronic/episodic/recent; VAS: visual analogue scale (0: no pain, 10: the worst imaginable pain); Occ/Par/Fr: occipital/parietal/frontal; R/E: rounded/elliptical.</p></fn>
<fn id="table-fn2-0333102412447537"><label>a</label><p>When considering patients instead of painful areas <italic>n</italic> is respectively 43 and 29.</p></fn>
<fn id="table-fn3-0333102412447537"><label>b</label><p>In response to preventatives <italic>N</italic> is 26 and 16, respectively.</p></fn>
<fn id="table-fn4-0333102412447537"><label>1</label><p><italic>t</italic>-test; <sup>2</sup>chi-squared test.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec4-0333102412447537" sec-type="discussion"><title>Discussion</title>
<p>Since the first description of nummular headache (<xref ref-type="bibr" rid="bibr1-0333102412447537">1</xref>), more than 200 cases have been described worldwide (<xref ref-type="bibr" rid="bibr3-0333102412447537">3</xref>). As we show in this series, NH is not an uncommon diagnosis in an outpatient headache office. In one hospital series, its incidence was 6.4/100,000/year (<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>) and in a study in a general neurology outpatient office it represented 1.25% of all patients attending due to a headache (<xref ref-type="bibr" rid="bibr6-0333102412447537">6</xref>). Originally, NH was described as a persistent, dull, mild to moderate head pain, felt exclusively in a circumscribed round or elliptical-shaped area typically 2–6 cm in diameter (<xref ref-type="bibr" rid="bibr1-0333102412447537">1</xref>,<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>,<xref ref-type="bibr" rid="bibr7-0333102412447537">7</xref>,<xref ref-type="bibr" rid="bibr8-0333102412447537">8</xref>).</p>
<p>NH has a female predominance and mean age of onset is around 40 years, as we have observed in our patients. Pain is usually located in the parietal scalp, although in our series there is a slight occipital predominance (<xref ref-type="bibr" rid="bibr7-0333102412447537">7</xref>).</p>
<p>Although not included in diagnostic ICHD-II criteria, superimposed exacerbations have been described from early reports of NH. They may last for several seconds or gradually increase up to hours (<xref ref-type="bibr" rid="bibr1-0333102412447537">1</xref>,<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>). Exacerbations are noticed as being more intense than basal pain, and mainly with a throbbing, electric or stabbing quality; in our series most of them were stabbing. They may be precipitated by touching the symptomatic area (<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>,<xref ref-type="bibr" rid="bibr8-0333102412447537">8</xref>–<xref ref-type="bibr" rid="bibr12-0333102412447537">12</xref>) and, as we have observed in our series, by head movements or Valsalva manoeuvres. The existence of pain attacks with no baseline pain (<xref ref-type="bibr" rid="bibr9-0333102412447537">9</xref>,<xref ref-type="bibr" rid="bibr13-0333102412447537">13</xref>) has also been described; nevertheless, we think that differentiation with primary stabbing headache is particularly difficult in such cases (<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>).</p>
<p>We have reviewed NH published cases with enough information about the presence of exacerbations and comparative characteristics between ENH and NENH patients. <xref ref-type="table" rid="table3-0333102412447537">Table 3</xref> shows the larger series in the literature (<xref ref-type="bibr" rid="bibr1-0333102412447537">1</xref>,<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>,<xref ref-type="bibr" rid="bibr8-0333102412447537">8</xref>,<xref ref-type="bibr" rid="bibr9-0333102412447537">9</xref>,<xref ref-type="bibr" rid="bibr14-0333102412447537">14</xref>–<xref ref-type="bibr" rid="bibr18-0333102412447537">18</xref>), with usually scarce information about characteristics of exacerbations and baseline pain in ENH cases.
<table-wrap id="table3-0333102412447537" position="float"><label>Table 3.</label><caption><p>Demographic and clinical features of NH cases including exacerbations in larger published series.</p></caption>
<graphic alternate-form-of="table3-0333102412447537" xlink:href="10.1177_0333102412447537-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th align="left">Reference NH (<italic>n</italic>)</th>
<th align="left">ENH <italic>n</italic> (%)</th>
<th align="left">Sex NH ENH-NENH</th>
<th align="left">Age at onset Years, mean (range) NH ENH-NENH</th>
<th align="left">Duration of exacerbations</th>
<th align="left">Baseline character NH ENH-NENH</th>
<th align="left">Character of exacerbations</th>
<th align="left">Intensity Basal NH Exacerbations Basal ENH- NENH (VAS)</th></tr></thead>
<tbody align="left">
<tr>
<td align="justify">Pareja et al., 2002 (<xref ref-type="bibr" rid="bibr1-0333102412447537">1</xref>) (<italic>n</italic>:13)</td>
<td align="left">8 (60%)</td>
<td align="left">8F/5M 5F/3M – 3F/2M</td>
<td align="left">52 (26–70) NS</td>
<td align="left">Seconds to 2 hours</td>
<td align="left">53% pressing NS</td>
<td align="left">Lancinating</td>
<td align="left">3 NS NS</td></tr>
<tr>
<td align="justify">Pareja et al., 2004 (<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>) (<italic>n</italic>:14)</td>
<td align="left">8 (57.1%)</td>
<td align="left">11F/3M NS</td>
<td align="left">38 (13–72) NS</td>
<td align="left">20 seconds to 5 minutes</td>
<td align="left">NS NS</td>
<td align="left">NS</td>
<td align="left">NS 6–9 NS</td></tr>
<tr>
<td align="justify">Dach et al., 2006 (<xref ref-type="bibr" rid="bibr14-0333102412447537">14</xref>) (<italic>n</italic>:3)</td>
<td align="left">1 (33%)</td>
<td align="left">1F/2M 0F/1M – 1F/1M</td>
<td align="left">18 (6–29) 19–13 (6–29)</td>
<td align="left">hours</td>
<td align="left">Variable Burning – pressing</td>
<td align="left">NS</td>
<td align="left">NS NS NS</td></tr>
<tr>
<td align="justify">Mathew et al., 2008 (<xref ref-type="bibr" rid="bibr15-0333102412447537">15</xref>) (<italic>n</italic>:4)</td>
<td align="left">4 (100%)</td>
<td align="left">4F/0M</td>
<td align="left">42 (35–58)</td>
<td align="left">NS</td>
<td align="left">NS</td>
<td align="left">NS</td>
<td align="left">NS NS</td></tr>
<tr>
<td align="justify">Dusitanond et al., 2008 (<xref ref-type="bibr" rid="bibr17-0333102412447537">17</xref>) (<italic>n</italic>:5)</td>
<td align="left">NS</td>
<td align="left">5F/0M</td>
<td align="left">24–59</td>
<td align="left">NS</td>
<td align="left">NS</td>
<td align="left">NS</td>
<td align="left">NS</td></tr>
<tr>
<td align="justify">Zhu et al., 2008 (<xref ref-type="bibr" rid="bibr18-0333102412447537">18</xref>) (<italic>n</italic>:21)</td>
<td align="left">NS</td>
<td align="left">12F/9M</td>
<td align="left">18–63</td>
<td align="left">NS</td>
<td align="left">NS</td>
<td align="left">NS</td>
<td align="left">NS</td></tr>
<tr>
<td align="justify">Alvaro et al., 2009 (<xref ref-type="bibr" rid="bibr16-0333102412447537">16</xref>) (<italic>n</italic>:4)</td>
<td align="left">3 (75%)</td>
<td align="left">3F/1M 2F/1M – 1F/0M</td>
<td align="left">46 (30–65) 43.3 (30–65) − 54</td>
<td align="left">hours</td>
<td align="left">Pressing – throbbing NS</td>
<td align="left">NS</td>
<td align="left">NS NS NS</td></tr>
<tr>
<td align="justify">Ruscheweyh et al., 2010 (<xref ref-type="bibr" rid="bibr13-0333102412447537">13</xref>) (<italic>n</italic>:6)</td>
<td align="left">4 (66.6%)</td>
<td align="left">5F/1M 3F/1M – 1F/0M</td>
<td align="left">39 (25–57) 40 (25–57) − 36 (24–49)</td>
<td align="left">seconds</td>
<td align="left">Pressing Pressing (50% no basal pain)</td>
<td align="left">Lancinating</td>
<td align="left">3.7 (<xref ref-type="bibr" rid="bibr2-0333102412447537">2</xref>–<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>) 7.2 (<xref ref-type="bibr" rid="bibr6-0333102412447537">6</xref>–<xref ref-type="bibr" rid="bibr8-0333102412447537">8</xref>) 3–4.5</td></tr>
<tr>
<td align="justify">Moon et al., 2010 (<xref ref-type="bibr" rid="bibr9-0333102412447537">9</xref>) (<italic>n</italic>:16)</td>
<td align="left">12 (75%)</td>
<td align="left">10F/6M NS</td>
<td align="left">50 (19–79) NS</td>
<td align="left">NS</td>
<td align="left">Dull NS</td>
<td align="left">NS</td>
<td align="left">NS</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0333102412447537"><p>NH: nummular headache; ENH: exacerbations nummular headache; NENH: non-exacerbations nummular headache; NS: not specified; F: female; M: male; VAS: visual analogue scale (0: no pain, 10: the worst imaginable pain).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The exact aetiology of NH is not clear, although it appears to be a local pain disorder with sensitization restricted to the symptomatic area, probably stemming from epicranial tissues, such as the terminal branches of sensory nerves (<xref ref-type="bibr" rid="bibr9-0333102412447537">9</xref>,<xref ref-type="bibr" rid="bibr13-0333102412447537">13</xref>,<xref ref-type="bibr" rid="bibr19-0333102412447537">19</xref>–<xref ref-type="bibr" rid="bibr22-0333102412447537">22</xref>). In the same way as neuropathies of peripheral nerves, in NH there is a variable combination of either continuous or paroxysmal spontaneous pain, stimulus-evoked pain, trophic changes (<xref ref-type="bibr" rid="bibr23-0333102412447537">23</xref>) and sensory signs. Pain paroxysms may be consistent with the terminal branch neuropathy hypothesis of NH (<xref ref-type="bibr" rid="bibr13-0333102412447537">13</xref>).</p>
<p>Regarding treatment, our first series affirmed that treatment was generally not necessary and it was enough for patients to be informed about the benign nature of their pain; when needed, standard doses of paracetamol usually sufficed (<xref ref-type="bibr" rid="bibr1-0333102412447537">1</xref>,<xref ref-type="bibr" rid="bibr5-0333102412447537">5</xref>). However, patients with NH often have an inadequate response not only to analgesics, but also to non-steroidal anti-inflammatory drugs (NSAIDs), opiates, oral steroids, or local infiltration with anaesthetics (<xref ref-type="bibr" rid="bibr7-0333102412447537">7</xref>,<xref ref-type="bibr" rid="bibr14-0333102412447537">14</xref>,<xref ref-type="bibr" rid="bibr15-0333102412447537">15</xref>,<xref ref-type="bibr" rid="bibr24-0333102412447537">24</xref>). Such patients should be assessed for the use of preventative therapy, considered necessary in 58% of our cases. There are no clear guidelines, as all we know about the management of these patients is based on small series or isolated cases. Gabapentin has been the most prescribed drug and has been suggested to be partially or completely effective in some case reports (<xref ref-type="bibr" rid="bibr7-0333102412447537">7</xref>,<xref ref-type="bibr" rid="bibr14-0333102412447537">14</xref>,<xref ref-type="bibr" rid="bibr19-0333102412447537">19</xref>), although results are inconsistent (<xref ref-type="bibr" rid="bibr8-0333102412447537">8</xref>–<xref ref-type="bibr" rid="bibr10-0333102412447537">10</xref>,<xref ref-type="bibr" rid="bibr16-0333102412447537">16</xref>,<xref ref-type="bibr" rid="bibr17-0333102412447537">17</xref>,<xref ref-type="bibr" rid="bibr25-0333102412447537">25</xref>). Botulinum toxin type A (BoNTA) has been used in a small number of patients with encouraging results, and appears to be effective in NH with inadequate response to other therapies (<xref ref-type="bibr" rid="bibr15-0333102412447537">15</xref>,<xref ref-type="bibr" rid="bibr17-0333102412447537">17</xref>). It has been recently supported with a Grade C recommendation (<xref ref-type="bibr" rid="bibr26-0333102412447537">26</xref>). Other preventatives such as tricyclic antidepressants (<xref ref-type="bibr" rid="bibr15-0333102412447537">15</xref>,<xref ref-type="bibr" rid="bibr24-0333102412447537">24</xref>,<xref ref-type="bibr" rid="bibr25-0333102412447537">25</xref>), topiramate (<xref ref-type="bibr" rid="bibr9-0333102412447537">9</xref>,<xref ref-type="bibr" rid="bibr13-0333102412447537">13</xref>), carbamazepine (<xref ref-type="bibr" rid="bibr9-0333102412447537">9</xref>), indomethacin (<xref ref-type="bibr" rid="bibr8-0333102412447537">8</xref>) or neurotropin (<xref ref-type="bibr" rid="bibr27-0333102412447537">27</xref>) have been helpful in some patients.</p>
<p>In our series more than 80% of patients achieved at last partial response with preventatives. We commonly used gabapentin at a dose of 600–2400 mg daily; BoNTA was not attempted on any of our patients. In our patients the presence of exacerbations was not related to relief with symptomatic therapy, or needing or response to preventatives.</p>
<p>In conclusion, <italic>in situ</italic> exacerbations are common in NH, a not infrequent diagnosis in a headache outpatient office. The presence and characteristics of exacerbations might be included in future diagnostic criteria. According to our comparative analysis of exacerbations and non-exacerbations cases in the larger series of NH published up to now, there are no demographic or clinical differences, including needing or response to therapy, between both populations. Nevertheless, sample size was probably still too small to show statistically significant differences.</p>
</sec>
</body>
<back>
<fn-group>
<fn id="fn1-0333102412447537"><label>*</label><p>Partially presented as a poster at the 2nd European Headache and Migraine Trust International Congress, Nice, October 2010.</p></fn>
</fn-group>
<sec id="sec5-0333102412447537"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0333102412447537"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pareja</surname><given-names>JA</given-names></name><name><surname>Caminero</surname><given-names>AB</given-names></name><name><surname>Serra</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Nummular headache: A coin-shaped cephalalgia</article-title>. <source>Neurology</source> <year>2002</year>; <volume>58</volume>: <fpage>1678</fpage>–<lpage>1679</lpage>.</citation></ref>
<ref id="bibr2-0333102412447537"><label>2</label><citation citation-type="journal"><collab>Headache Classification Subcommittee of the International Headache Society</collab>. <article-title>The International Classification of Headache Disorders: 2nd edition</article-title>. <source>Cephalalgia</source> <year>2004</year>; <volume>24</volume>(<issue>Suppl 1</issue>): <fpage>9</fpage>–<lpage>160</lpage>.</citation></ref>
<ref id="bibr3-0333102412447537"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cortijo</surname><given-names>E</given-names></name><name><surname>Guerrero-Peral</surname><given-names>AL</given-names></name><name><surname>Herrero-Velázquez</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Nummular headache: clinical features and therapeutic experience in a series of 30 new cases</article-title>. <source>Rev Neurol</source> <year>2011</year>; <volume>52</volume>: <fpage>72</fpage>–<lpage>80</lpage>.</citation></ref>
<ref id="bibr4-0333102412447537"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerrero</surname><given-names>AL</given-names></name><name><surname>Cuadrado</surname><given-names>ML</given-names></name><name><surname>García-García</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Bifocal nummular headache: A series of 6 new cases</article-title>. <source>Headache</source> <year>2011</year>; <volume>51</volume>: <fpage>1161</fpage>–<lpage>1166</lpage>.</citation></ref>
<ref id="bibr5-0333102412447537"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pareja</surname><given-names>JA</given-names></name><name><surname>Pareja</surname><given-names>J</given-names></name><name><surname>Barriga</surname><given-names>FJ</given-names></name><etal/></person-group>. <article-title>Nummular headache: A prospective series of 14 new cases</article-title>. <source>Headache</source> <year>2004</year>; <volume>44</volume>: <fpage>611</fpage>–<lpage>614</lpage>.</citation></ref>
<ref id="bibr6-0333102412447537"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerrero</surname><given-names>AL</given-names></name><name><surname>Martín-Polo</surname><given-names>J</given-names></name><name><surname>Gutiérrez</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Representation of the nummular headache in general consultation in neurology</article-title>. <source>Neurología</source> <year>2008</year>; <volume>23</volume>: <fpage>474</fpage>–<lpage>474</lpage>.</citation></ref>
<ref id="bibr7-0333102412447537"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grosberg</surname><given-names>BM</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group>. <article-title>Nummular headache</article-title>. <source>Curr Pain Headache Rep</source> <year>2007</year>; <volume>11</volume>: <fpage>310</fpage>–<lpage>312</lpage>.</citation></ref>
<ref id="bibr8-0333102412447537"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldacci</surname><given-names>F</given-names></name><name><surname>Nuti</surname><given-names>A</given-names></name><name><surname>Lucetti</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Nummular headache dramatically responsive to indomethacin</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>1151</fpage>–<lpage>1152</lpage>.</citation></ref>
<ref id="bibr9-0333102412447537"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>J</given-names></name><name><surname>Ahmed</surname><given-names>K</given-names></name><name><surname>Garza</surname><given-names>I</given-names></name></person-group>. <article-title>Case series of sixteen patients with nummular headache</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>1527</fpage>–<lpage>1530</lpage>.</citation></ref>
<ref id="bibr10-0333102412447537"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tayeb</surname><given-names>Z</given-names></name><name><surname>Hafeez</surname><given-names>F</given-names></name><name><surname>Shafiq</surname><given-names>Q</given-names></name></person-group>. <article-title>Successful treatment of nummular headache with TENS</article-title>. <source>Cephalalgia</source> <year>2008</year>; <volume>28</volume>: <fpage>897</fpage>–<lpage>898</lpage>.</citation></ref>
<ref id="bibr11-0333102412447537"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>ML</given-names></name><name><surname>Valle</surname><given-names>B</given-names></name><name><surname>Fernández-de-las-Peñas</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Bifocal nummular headache: the first three cases</article-title>. <source>Cephalalgia</source> <year>2009</year>; <volume>29</volume>: <fpage>583</fpage>–<lpage>586</lpage>.</citation></ref>
<ref id="bibr12-0333102412447537"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dabscheck</surname><given-names>G</given-names></name><name><surname>Andrews</surname><given-names>PI</given-names></name></person-group>. <article-title>Nummular headache associated with focal hair heterochromia in a child</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>1403</fpage>–<lpage>1405</lpage>.</citation></ref>
<ref id="bibr13-0333102412447537"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruscheweyh</surname><given-names>R</given-names></name><name><surname>Buchheister</surname><given-names>A</given-names></name><name><surname>Gregor</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Nummular headache: six new cases and lancinating pain attacks as possible manifestation</article-title>. <source>Cephalalgia</source> <year>2010</year>; <volume>30</volume>: <fpage>249</fpage>–<lpage>253</lpage>.</citation></ref>
<ref id="bibr14-0333102412447537"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dach</surname><given-names>F</given-names></name><name><surname>Specialli</surname><given-names>J</given-names></name><name><surname>Eckeli</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Nummular headache: three new cases</article-title>. <source>Cephalalgia</source> <year>2006</year>; <volume>26</volume>: <fpage>1234</fpage>–<lpage>1237</lpage>.</citation></ref>
<ref id="bibr15-0333102412447537"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>NT</given-names></name><name><surname>Kalaisam</surname><given-names>J</given-names></name><name><surname>Meadors</surname><given-names>L</given-names></name></person-group>. <article-title>Botulinum toxin type A for the treatment of nummular headache</article-title>. <source>Headache</source> <year>2008</year>; <volume>48</volume>: <fpage>442</fpage>–<lpage>447</lpage>.</citation></ref>
<ref id="bibr16-0333102412447537"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alvaro</surname><given-names>LC</given-names></name><name><surname>García</surname><given-names>JM</given-names></name><name><surname>Areitio</surname><given-names>E</given-names></name></person-group>. <article-title>Nummular headache: a series with symptomatic and primary cases</article-title>. <source>Cephalalgia</source> <year>2009</year>; <volume>29</volume>: <fpage>379</fpage>–<lpage>383</lpage>.</citation></ref>
<ref id="bibr17-0333102412447537"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dusitanond</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>W</given-names></name></person-group>. <article-title>Botulinum toxin type A’s efficacy in nummular headache</article-title>. <source>Headache</source> <year>2008</year>; <volume>48</volume>: <fpage>1379</fpage>–<lpage>1379</lpage>.</citation></ref>
<ref id="bibr18-0333102412447537"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>KY</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>Nummular headache: 21 new cases and therapeutic results</article-title>. <source>Zhonghua Yi Xue Za Zhi</source> <year>2008</year>; <volume>88</volume>: <fpage>2935</fpage>–<lpage>2937</lpage>.</citation></ref>
<ref id="bibr19-0333102412447537"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>RW</given-names></name><name><surname>Pareja</surname><given-names>JA</given-names></name></person-group>. <article-title>Nummular headache</article-title>. <source>Headache</source> <year>2005</year>; <volume>45</volume>: <fpage>164</fpage>–<lpage>165</lpage>.</citation></ref>
<ref id="bibr20-0333102412447537"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernández-de-las-Peñas</surname><given-names>C</given-names></name><name><surname>Cuadrado</surname><given-names>ML</given-names></name><name><surname>Barriga</surname><given-names>FJ</given-names></name><etal/></person-group>. <article-title>Local decrease of pressure pain threshold in nummular headache</article-title>. <source>Headache</source> <year>2006</year>; <volume>46</volume>: <fpage>1195</fpage>–<lpage>1198</lpage>.</citation></ref>
<ref id="bibr21-0333102412447537"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-de-las-Peñas</surname><given-names>C</given-names></name><name><surname>Cuadrado</surname><given-names>ML</given-names></name><name><surname>Barriga</surname><given-names>FJ</given-names></name><etal/></person-group>. <article-title>Pericranial tenderness is not related to nummular headache</article-title>. <source>Cephalalgia</source> <year>2007</year>; <volume>27</volume>: <fpage>182</fpage>–<lpage>186</lpage>.</citation></ref>
<ref id="bibr22-0333102412447537"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pareja</surname><given-names>JA</given-names></name><name><surname>Pareja</surname><given-names>J</given-names></name><name><surname>Yangüela</surname><given-names>J</given-names></name></person-group>. <article-title>Nummular headache, trochleitis, supraorbital neuralgia, and other epicranial headaches and neuralgias: the epicranias</article-title>. <source>J Headache Pain</source> <year>2003</year>; <volume>4</volume>: <fpage>125</fpage>–<lpage>131</lpage>.</citation></ref>
<ref id="bibr23-0333102412447537"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pareja</surname><given-names>JA</given-names></name><name><surname>Cuadrado</surname><given-names>ML</given-names></name><name><surname>Fernández-de-las-Peñas</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Nummular headache with tropic changes inside the painful area</article-title>. <source>Cephalalgia</source> <year>2008</year>; <volume>28</volume>: <fpage>186</fpage>–<lpage>190</lpage>.</citation></ref>
<ref id="bibr24-0333102412447537"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trucco</surname><given-names>M</given-names></name><name><surname>Mainardi</surname><given-names>F</given-names></name><name><surname>Perego</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Nummular headache: first Italian case and therapeutic proposal</article-title>. <source>Cephalalgia</source> <year>2006</year>; <volume>26</volume>: <fpage>354</fpage>–<lpage>356</lpage>.</citation></ref>
<ref id="bibr25-0333102412447537"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trucco</surname><given-names>M</given-names></name></person-group>. <article-title>Nummular headache: another case treated with gabapentin</article-title>. <source>J Headache Pain</source> <year>2007</year>; <volume>8</volume>: <fpage>137</fpage>–<lpage>138</lpage>.</citation></ref>
<ref id="bibr26-0333102412447537"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linde</surname><given-names>M</given-names></name><name><surname>Hagen</surname><given-names>K</given-names></name><name><surname>Stovner</surname><given-names>LJ</given-names></name></person-group>. <article-title>Botulinum toxin treatment of secondary headaches and cranial neuralgias: a review of evidence</article-title>. <source>Acta Neurol Scand Suppl</source> <year>2011</year>; <volume>191</volume>: <fpage>50</fpage>–<lpage>55</lpage>.</citation></ref>
<ref id="bibr27-0333102412447537"><label>27</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Kobatake</surname><given-names>K</given-names></name></person-group>. <article-title>Successful treatment of nummular headache with Neurotropin®</article-title>. <source>J Headache Pain.</source> <comment>Epub ahead of print 9 Sept 2011</comment>.</citation></ref>
</ref-list>
</back>
</article>